Key result
Limosilactobacillus fermentum ACA-DC 179 reduces atherosclerotic lesions and triglycerides in mice.
Why the study?
Does Limosilactobacillus fermentum ACA-DC 179 oral administration attenuate atherosclerosis progression in ApoE-/- mice?
Does Limosilactobacillus fermentum ACA-DC 179 oral administration attenuate atherosclerosis progression in ApoE-/- mice?
Answers are grounded in this paper and cite their sources.
Oral administration of high-dose Limosilactobacillus fermentum ACA-DC 179 attenuates atherosclerosis progression and reduces triglycerides in ApoE-/- mice, potentially mediated by gut microbiota modulation.
Recent research findings have established a close relationship between gut microbiota and atherosclerosis development; hence, focus has shifted towards modifying gut microbiota through probiotics administration. We thereby investigated the impact of Limosilactobacillus fermentum ACA-DC 179 on the progression of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice. Twelve-week-old ApoE-/- male and female mice were treated with low (106 CFU/mouse) or high (109 CFU/mouse) dose of L. fermentum ACA-DC 179 daily for 8 weeks. Microbiota of faeces during intervention and of gut content at study end was determined using classical microbiological and metataxonomic analyses. Additionally, blood serum biochemical markers and atherosclerotic lesions were evaluated in all animal groups. Classical microbiological analysis revealed high counts of Lactobacillus spp., Bifidobacterium spp. and Clostridium spp. for both male and female animals, regardless the treatment; however, at study end, L. fermentum ACA-DC 179 high dose managed to significantly increase Lactobacillus spp. counts of faeces of male mice. Metataxonomic analysis of faeces and gut content revealed significant differences among animal groups regarding either intestinal compartment, namely jejunum, ileum or colon, or probiotic treatment. A decrease in Lachnoclostridium and an increase in Erysipelatoclostridium were observed in faecal samples following probiotic treatment. This effect was consistent with the results obtained for all gut compartment samples of mice receiving the high dose of L. fermentum ACA-DC 179. Concerning main metabolism-related blood biomarkers, triglycerides decreased in animal groups of both sexes receiving L. fermentum ACA-DC 179. Moreover, L. fermentum ACA-DC 179 high dose significantly reduced atherosclerotic lesions in both male and female mice. Overall, our findings indicate that L. fermentum ACA-DC 179 administration attenuated the development of atherosclerosis in ApoE-/- mice supporting its beneficial potential in relevant human studies. Altered gut microbiota seems to play a significant role to this phenomenon and further studies should be conducted to elucidate underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Ferrocino et al. (2025) studied Atherosclerosis. Limosilactobacillus fermentum ACA-DC 179 was evaluated on Atherosclerotic lesions and blood serum biochemical markers. High dose Limosilactobacillus fermentum ACA-DC 179 significantly reduced atherosclerotic lesions and decreased triglycerides in both male and female ApoE-/- mice.
Synapse has enriched 10 related papers. Consider them for comparative context: